Physician profile
Vincent R Bonagura
NPI 1568556629
$137,838.24
in general payments reported to CMS, 2019-2025
6 companies · $11K in 2025
The $11K reported for 2025 was more than what 86% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $23K · 2021: $9,854 · 2022: $22K · 2023: $12K · 2024: $25K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $7,827 · Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,610.00 |
| Travel and Lodging | $7,826.92 |
| Food and Beverage | $1,210.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $92,748.63 | 2019-2025 | Hizentra |
| Shire North American Group INC | $20,322.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15,880.45 | 2020-2025 | Cuvitru |
| Grifols USA, LLC | $8,830.88 | 2019-2021 | |
| Genentech USA, INC. | $40.60 | 2019 | |
| Alk-Abello, INC | $15.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Bonagura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.